Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$2.69
-4.6%
$2.85
$1.72
$15.70
$3.26M0.31.00 million shs22,153 shs
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$0.04
+3.7%
$0.04
$0.02
$0.05
$809K0.2710,799 shs2,752 shs
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
$2.54
+0.6%
$2.42
$2.00
$13.95
$3.37M0.41269,597 shs2,591 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-37.30%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-1.40%-2.76%+1.81%+2.92%-45.60%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
+3.69%+7.67%+9.94%-6.41%-15.49%
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
+3.64%+2.65%-3.03%+1.35%+255,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.0567 of 5 stars
0.05.00.00.02.40.00.6
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/AN/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
1.8913 of 5 stars
3.54.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00
N/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
0.00
N/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
3.00
Buy$33.001,201.78% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.60M0.71N/AN/A$20.64 per share0.13
Kaya Holdings, Inc. stock logo
KAYS
Kaya
$10K80.92N/AN/A($0.77) per share-0.05
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/AN/AN/AN/A$24.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$7.68M-$12.09N/AN/A-168.87%-107.93%-82.97%9/29/2025 (Estimated)
Kaya Holdings, Inc. stock logo
KAYS
Kaya
-$2.08M-$0.08N/AN/AN/AN/A-1,044.25%8/13/2025 (Estimated)
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)

Latest KAYS, GENE, INM, and PPBT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A-$0.04N/A-$0.04N/A$0.01 million
5/21/2025Q1 2025
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/A-$0.17N/A-$0.17N/AN/A
5/12/2025Q3 2025
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$1.94N/A-$1.94N/A$1.26 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/AN/AN/AN/AN/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.06
3.49
3.04
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
0.01
0.01
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
N/A
2.72
2.72

Institutional Ownership

CompanyInstitutional Ownership
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
N/A
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
9.64%

Insider Ownership

CompanyInsider Ownership
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
1.43%
Kaya Holdings, Inc. stock logo
KAYS
Kaya
23.52%
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
2.98%
CompanyEmployeesShares OutstandingFree FloatOptionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
101.21 million1.19 millionNot Optionable
Kaya Holdings, Inc. stock logo
KAYS
Kaya
422.17 million16.96 millionNot Optionable
Purple Biotech Ltd. Sponsored ADR stock logo
PPBT
Purple Biotech
201.33 million1.29 millionOptionable

Recent News About These Companies

Purple Biotech Stock Price History - Investing.com
Purple Biotech appoints Shai Lankry as new CFO
Purple Biotech announces publication of study on potential of NT219
Purple Biotech reports Q4 EPS (26c) vs. ($3.80) last year
Purple Biotech sees cash runway into mid-2026

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

$0.76 0.00 (0.00%)
As of 05/20/2025

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$2.69 -0.13 (-4.61%)
As of 10:57 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Kaya stock logo

Kaya OTCMKTS:KAYS

$0.04 +0.00 (+3.69%)
As of 07/10/2025 01:56 PM Eastern

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.

Purple Biotech stock logo

Purple Biotech NASDAQ:PPBT

$2.54 +0.02 (+0.60%)
As of 10:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.